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Prolonged dual antiplatelet therapy in stable coronary disease: 
comparative observational study of benefits and harms in 
unselected versus trial populations
A Timmis,1,2 E Rapsomaniki,1 S C Chung,1 M Pujades-Rodriguez,1 A Moayyeri,1 D Stogiannis,3  
A D Shah,1 L Pasea,1 S Denaxas,1 C Emmas,4 H Hemingway1 
ABSTRACT
ObjeCtive
To estimate the potential magnitude in unselected 
patients of the benefits and harms of prolonged dual 
antiplatelet therapy after acute myocardial infarction 
seen in selected patients with high risk characteristics 
in trials.
Design
Observational population based cohort study.
setting
PEGASUS-TIMI-54 trial population and CALIBER 
(ClinicAl research using LInked Bespoke studies and 
Electronic health Records).
PartiCiPants
7238 patients who survived a year or more after acute 
myocardial infarction.
interventiOns
Prolonged dual antiplatelet therapy after acute 
myocardial infarction.
Main OutCOMe Measures
Recurrent acute myocardial infarction, stroke, or fatal 
cardiovascular disease. Fatal, severe, or intracranial 
bleeding.
results
1676/7238 (23.1%) patients met trial inclusion and 
exclusion criteria (“target” population). Compared with 
the placebo arm in the trial population, in the target 
population the median age was 12 years higher, there 
were more women (48.6% v 24.3%), and there was a 
substantially higher cumulative three year risk of both 
the primary (benefit) trial endpoint of recurrent acute 
myocardial infarction, stroke, or fatal cardiovascular 
disease (18.8% (95% confidence interval 16.3% to 
21.8%) v 9.04%) and the primary (harm) endpoint of 
fatal, severe, or intracranial bleeding (3.0% (2.0% to 
4.4%) v 1.26% (TIMI major bleeding)). Application of 
intention to treat relative risks from the trial (ticagrelor 
60 mg daily arm) to CALIBER’s target population 
showed an estimated 101 (95% confidence interval 87 
to 117) ischaemic events prevented per 10 000 treated 
per year and an estimated 75 (50 to 110) excess fatal, 
severe, or intracranial bleeds caused per 10 000 
patients treated per year. Generalisation from 
CALIBER’s target subgroup to all 7238 real world 
patients who were stable at least one year after acute 
myocardial infarction showed similar three year risks 
of ischaemic events (17.2%, 16.0% to 18.5%), with an 
estimated 92 (86 to 99) events prevented per 10 000 
patients treated per year, and similar three year risks 
of bleeding events (2.3%, 1.8% to 2.9%), with an 
estimated 58 (45 to 73) events caused per 10 000 
patients treated per year.
COnClusiOns
This novel use of primary-secondary care linked 
electronic health records allows characterisation of 
“healthy trial participant” effects and confirms the 
potential absolute benefits and harms of dual 
antiplatelet therapy in representative patients a year or 
more after acute myocardial infarction.
Introduction
National and international guidelines recommend the 
long term use of a range of treatments after acute myo-
cardial infarction, but dual antiplatelet therapy with a 
P2Y12 receptor antagonist (clopidogrel, prasugrel, or 
ticagrelor) and aspirin is currently recommended for 
only up to one year.1-3  With increasing survival after the 
acute phase of myocardial infarction, however, there is 
a burgeoning population of stable patients requiring 
long term management for whom recent evidence from 
trials suggests that prolonging dual antiplatelet ther-
apy beyond one year could provide continuing protec-
tion against cardiovascular events. The Prevention of 
Cardiovascular Events in Patients with Prior Heart 
Attack Using Ticagrelor Compared to Placebo on a 
Background of Aspirin (PEGASUS-TIMI-54) trial 
enrolled patients one to three years after an index acute 
myocardial infarction and showed that dual antiplate-
let therapy with ticagrelor 60 mg compared with mono-
therapy with aspirin reduced the risk of cardiovascular 
death, myocardial infarction, or stroke by 16% but 
increased the risk of major bleeding by a factor of 2.4.4 
WhAT IS AlReAdy knoWn on ThIS TopIC
Lifelong combinations of drug treatments are recommended for secondary 
prevention after acute myocardial infarction
The recent PEGASUS-TIMI-54 trial showed that prolonged dual antiplatelet therapy 
(addition of ticagrelor to low dose aspirin) in patients who had already survived to 
the first anniversary of their heart attack reduced the risk of ischaemic events but 
increased the risk of major bleeding
WhAT ThIS STudy AddS
About a quarter of unselected patients a year or more after acute myocardial 
infarction might meet trial inclusion and exclusion criteria for treatment
Risk of recurrent acute myocardial infarction, stroke, or cardiovascular death in the 
next three years in these “target” patients was nearly 19%, twice the risk seen in the 
trial; this risk was similar (17%) in unselected (“real world”) patients
The potential for dual antiplatelet therapy to deliver clinical benefit a year or more 
after acute myocardial infarction is likely to be greatest in high risk subgroups 
without previous stroke or recent anticoagulation
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Other studies on acute coronary syndrome have also 
reported point estimates for major adverse cardiac 
events favouring extended dual antiplatelet therapy 
compared with aspirin monotherapy; a contemporary 
meta-analysis reporting a 22% reduction in relative 
risk.5  These studies must be distinguished from those in 
percutaneous coronary intervention, in which dual 
antiplatelet therapy for less than a year seems effective 
for protecting against drug eluting stent thrombosis in 
most patients.6
It is not known how the balance of benefit and harm 
of extended dual antiplatelet therapy applies to the 
general population of unselected patients who survive 
the first year after acute myocardial infarction. Although 
it has been widely observed that event rates reported in 
trials tend to be lower than those reported in observa-
tional studies of hospital populations, patients in the 
PEGASUS-TIMI-54 trial were selected on “high risk” 
characteristics (age >65, renal impairment, two or more 
myocardial infarctions, and diabetes) to enhance the 
potential benefit of treatment. Registry outcome data 
for patients with acute coronary syndromes are often 
restricted to the first year.7  Patients who survive a year 
or more are an under-studied group, largely managed in 
primary care, for whom cardiovascular event rates have 
not been well defined. Population based electronic 
health records, such as those that exist in the United 
Kingdom, particularly when linked with disease, hospi-
tal admissions, and death registry data, provide a 
means of obtaining information on patient characteris-
tics and outcomes that can then be compared with the 
more selected populations recruited within randomised 
controlled trials.8-11 This approach has the potential to 
put into a public health context the interpretation of 
trial findings, but there have been few, if any, previous 
direct comparisons of trial risks with those from popu-
lation based linked electronic health records.
We compared clinically representative populations 
with acute myocardial infarction drawn from CALIBER 
(ClinicAl research using LInked Bespoke studies and 
Electronic health Records) with the patients recruited 
into the PEGASUS-TIMI-54 trial. We examined patients’ 
characteristics, cardiovascular event rates, and rates of 
hospital admission for bleeding in the CALIBER popu-
lations meeting trial inclusion and exclusion criteria 
and compared these with patients participating in the 
PEGASUS-TIMI-54 trial to determine how this might 
affect clinical application of the results and the selec-
tion of patients for treatment with dual antiplatelet 
therapy a year or more after acute myocardial infarc-
tion.
Methods
Data sources
This observational cohort study was based on the CAL-
IBER platform with linked electronic health records 
across primary care (the Clinical Practice Research 
Datalink (CPRD)), acute coronary syndrome registry 
(the Myocardial Ischaemia National Audit Project 
(MINAP)), hospital care (hospital episodes statistics), 
and cause specific mortality (Office for National 
 Statistics).12  The CALIBER dataset comprises popula-
tion based longitudinal patient data from linked elec-
tronic health records. The patients included have been 
shown to be representative of the whole population of 
England in terms of age, sex, ethnicity, and overall mor-
tality,13-15  and we have extensively validated cardiovas-
cular risk factors, including age, sex, deprivation, 
smoking, blood pressure, and type 2 diabetes, against a 
wide range of cardiovascular diseases.16-20 CALIBER 
contains primary care data from CPRD, with informa-
tion on anthropometric measurements, laboratory 
tests, clinical diagnoses (coded with the Read clinical 
coding system), prescriptions (recorded with Multilex), 
and medical procedures. MINAP is a national registry of 
patients admitted to hospital with acute coronary syn-
dromes. Hospital episode statistics provide information 
on diagnoses (coded with ICD-10 (international classifi-
cation of diseases, 10th revision)) and medical proce-
dures (coded with the Office of Population Censuses 
and Surveys—Classification of Interventions and Proce-
dures, version 4 (OPCS-4)) related to all elective and 
emergency hospital admissions across all NHS 
(National Health Service) hospitals in England.
study populations
The CALIBER population was selected from patients 
admitted to hospital with a primary diagnosis of acute 
coronary syndrome (acute myocardial infarction or 
unstable angina) from April 2005 to March 2010 (fig 1 ), 
before ticagrelor was in use in the UK. A “real world” 
population of patients who were stable after acute myo-
cardial infarction was identified, comprising 7328 
patients who survived at least a year after the index 
admission, remained registered with the participating 
general practice, and had no further admissions for 
acute myocardial infarction during the year. From this 
real world population, we identified two further CALI-
BER populations. The first was a “high risk” population 
of 5279 patients who met the inclusion criteria for PEG-
ASUS-TIMI-54 (age ≥65, or ≥50 with diabetes, renal dis-
ease, or a second previous myocardial infarction). We 
were unable to select on the basis of multivessel coro-
nary disease, which was not coded in CALIBER. The 
second population comprised a “target population” of 
1676 patients eligible for PEGASUS-TIMI-54 who met the 
trial’s high risk inclusion criteria (see above) and also 
exclusion criteria (listed against 3603 patients, fig 1). 
We set the study entry date (stable myocardial infarc-
tion date) to 12 months after the date of index acute 
myocardial infarction. Patients were followed up until 
death, transfer out of the general practice, or end of the 
study period (24 March 2010). Patients’ characteristics 
in the three CALIBER populations were compared with 
each other and with the trial participants.
baseline characteristics
We recorded age, sex, body mass index (BMI), smoking 
status (current, former, never), diabetes (use of insulin, 
metformin, or sulphonamides or a diagnosis recorded 
any time before study entry), diagnosis of hypertension, 
percutaneous coronary intervention or coronary artery 
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bypass grafting procedures performed in the 12 month 
period between the index event and study entry date, 
and medical history (more than one hospital admission 
for acute myocardial infarction, renal disease, heart 
failure, peripheral arterial disease, atrial fibrillation, 
stroke, hospital admission for bleeding, chronic 
obstructive pulmonary disease, cancer, and dementia 
(diagnostic codes or drugs for treatment)), as recorded 
in primary or secondary care before the study entry 
date. Moderate/severe renal disease was defined on the 
basis of diagnoses in secondary care. ST elevation myo-
cardial infarction (STEMI)/non-STEMI was determined 
from MINAP in 80% of cases but was unspecified in the 
remainder for whom the type of acute myocardial 
infarction was imputed based on ICD-10 code for hospi-
tal admission.21 Before imputation we tested the method 
in patients with documented acute myocardial infarc-
tion phenotype, showing agreement in 86% of cases. 
Diagnosis ICD-10 codes and phenotyping algorithms 
are available via the https://www.caliberresearch.org/
portal online resource.
endpoints
The cardiovascular endpoint, matching the primary 
efficacy endpoint in the trial, was a composite of acute 
myocardial infarction, stroke, or death from cardiovas-
cular disease. The bleeding endpoint, a proxy for the 
primary safety endpoint of TIMI major bleeding in the 
trial, was “fatal, severe, or intracranial bleeding” 
defined as a composite of fatal bleeding, bleeding 
requiring transfusion, hospital admission for bleeding 
with length of stay seven days or more, or intracranial 
bleeding (ICD-10 codes shown in table A in appendix 1). 
We also analysed fatal or intracranial bleeding, defined 
as bleeding recorded as the primary cause of death, 
hospital admission for bleeding within seven days 
before death, or hospital admission for intracranial 
bleeding (appendix 1).
Patterns of drug treatment for cardiovascular disease
We examined patterns in drug use for secondary pre-
vention of cardiovascular disease, including statins, 
aspirin, ADP inhibitor antiplatelet agents (mostly clopi-
dogrel), dual antiplatelet therapy (aspirin combined 
with another antiplatelet agent), β blockers, angioten-
sin converting enzyme inhibitors (ACEIs), angiotensin 
receptor blockers (ARBs), oral anticoagulants (99% 
warfarin), proton pump inhibitors, and antidiabetic 
drugs. British National Formulary (BNF) codes for drugs 
are available in table B in appendix 1. Beginning from 
the index admission for acute myocardial infarction 
and for the first, second, and third years of follow-up 
since the date patients were stable after myocardial 
infarction (a year after acute index admission), we 
assessed the prescription continuation rates (period 
between the first and last prescription date assuming 
complete adherence within this interval) adjusted for 
censoring (cardiovascular event, death, or lost to fol-
low-up) by the Kaplan-Meier method. Prescription use 
at baseline was classified as current/recent if the most 
recent prescription was active at the index date or 
ended within the 30 days before the index date.
statistical analysis
For each endpoint we estimated the incidence rate 
(total number of events observed divided by the total 
number of person years of observation), events per 
patient year rates during follow-up, and by specific time 
periods (0-1, 2-3, >3 years during period of stability) in 
each patient population. We applied the intention to 
treat relative risks from the trial (ticagrelor 60 mg data) 
to CALIBER study populations to estimate the number 
of ischaemic events prevented or fatal, severe, or 
 intracranial bleeds caused per 10 000 treated per year. 
We compared observed risks between the different 
study populations by estimating the cumulative risks 
and 95% confidence intervals over the first three years 
of follow-up. In the population after myocardial 
 infarction we evaluated the prognostic ability of clinical 
characteristics with respect to ischaemic outcome 
based on risks from the Cox proportional hazards model 
adjusted for age, sex, history of diabetes, more than one 
previous acute myocardial infarction, and eGFR <60 
mL/min/1.73m2. Data were complete for all adjustment 
factors except eGFR, which was 86% complete, and 
hazard ratios were therefore estimated in complete 
cases analyses. We verified the proportional hazards 
assumption of the Cox model by plotting the 
Real world population
Survivors aer AMI (n=7238)
High risk population
Survivors aer AMI (n=5279)
Target population
Survivors aer MI eligible for
PEGASUS-TIMI-54 (n=1676)
Patients did not meet trial
inclusion criteria (age ≥65, or
≥50 with diabetes, renal disease
(eGFR <60mL/min/1.73m2) or
second previous AMI*(n=1959) 
Patients met further trial exclusion
criteria (n=3603):
1. Use of ADP receptor blockers (n=2628)
2. Planned revascularisation (n=745)
3. CYP3A inhibitors use (n=62)
4. Oral anticoagulant therapy (n=0)
5. Bleeding diathesis (n=15)
6a. Intracranial bleed (n=81)
6b. CNS tumour (n=1)
6b1. Intracranial/spinal surgery (n=25)
6c. GI bleed (n=74)
6d. Major surgery (n=121)
7. H/O stroke (n=202)
8. AV block (n=453)
9. CABG in past 5 years (n=532)
10. Severe liver disease (n=91)
11. Renal failure requiring dialysis (n=41)
12. Pregnancy (n=3) 
*Medical history of >1 MI and stroke based on hospital admissions
(primary/secondary diagnoses) up to date of entry to survivor cohort
(1 year aer index MI)
Fig 1 | selection of participants who survived one year or 
more after myocardial infarction (Mi) from Caliber, april 
2005-March 2010
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 Schoenfield residuals. All analyses were performed 
with the statistical package R (version 15.2), SAS (ver-
sion 9.3) and STATA (version 13.1).
bias
Our real world patients were sourced from linked elec-
tronic health records, without exclusion and with >96% 
successful matching across CALIBER’s four data 
sources.11 12 Biases in recruitment and follow-up were 
thereby minimised while the ascertainment of cardio-
vascular outcomes was enhanced.
Patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
developing plans for design or implementation of the 
study. No patients were asked to advise on interpreta-
tion or writing up of results. There are no plans to dis-
seminate the results of the research to study participants 
or the relevant patient community. 
Results
The “real world” population for our analysis comprised 
7238 patients recorded in CALIBER with acute myocar-
dial infarction who survived for a year or more without 
another infarction (fig 1 ). From this population we iden-
tified a “high risk” population of 5279 (72.9%) patients 
who met the PEGASUS-TIMI-54 trial inclusion criteria 
and a “target” population of 1676 (23.1%) patients who 
met both the inclusion and exclusion criteria for the 
trial (table 1). Follow-up, starting 12 months after the 
index event, was for a median of 1.5 (interquartile range 
0.7-2.5) years.
Population characteristics
The CALIBER target population was older (median age 
12 years higher) and included proportionately more 
women and more patients with non-STEMI compared 
with the PEGASUS-TIMI-54 trial population (table 1). 
Differences were similar for CALIBER’s high risk popu-
lation and were only slightly less for CALIBER’s real 
world population. Analysis of the high risk inclusion 
criteria for the trial showed that age ≥65 characterised 
90%, 89%, and 64% of CALIBER’s target, high risk, and 
real world populations, respectively, compared with 
55% of the PEGASUS-TIMI-54 trial population. Renal 
dysfunction (eGFR <60 mL/min/1.73m2) was also more 
prevalent in the CALIBER populations, but other risk 
factors, including second previous acute myocardial 
infarction and diabetes, were less prevalent compared 
with the trial. Baseline use of aspirin, β blockers, and 
statins was lower in the three CALIBER populations 
compared with the trial (table 1 ), and for each CALIBER 
population there were parallel declines in use during 
table 1 | baseline characteristics of populations of patients who survived acute myocardial infarction (aMi) defined in 
this study and equivalent characteristics from Pegasus-tiMi-54 trial. Figures are numbers (percentage) unless stated 
otherwise
Caliber observational data from population of england
Pegasus-tiMi-54 
placebo group 
(n=7067)
all post-Mi 
survivors “real 
world” (n=7328)
Met trial inclusion 
criteria “high 
risk” (n=5279)
Met trial inclusion 
and exclusion criteria 
“target” (n=1676)
Index myocardial infarction:
 STEMI 2827 (39.1) 1809 (34.3) 599 (35.7) 3809 (54.0)
 Non-STEMI 4411 (60.9) 3470 (65.7) 1077 (64.3) 2843 (40.3)
Median (IQR) years after index AMI 1.0 (1-1) 1.0 (1-1) 1.0 (1-1) 1.7 (1.2-1.3)
Baseline characteristics:
 Mean (SD) age (years) 69.6 (13.0) 75.3 (9.5) 77.0 (9.6) 65.4 (8.3)
 Women 2461 (34.0) 2088 (39.6) 814 (48.6) 1717 (24.3)
 White 5924 (94.4) 4174 (94.2) 1350 (95.7) 6124 (86.7)
 Mean (SD) weight (kg)* 79.6 (17.5) 77.2 (16.8) 74.8 (17.4) 81.8 (16.6)
 Hypertension 4543 (62.8) 3677 (69.7) 1090 (65.0) 5484 (77.6)
 Hypercholesterolemia NA NA NA 5451 (77.1)
 Current smoker* 1065 (15.7) 572 (11.6) 162 (10.6) 1143 (16.2)
 Diabetes mellitus 1522 (21.0) 1449 (27.5) 392 (24.4) 2257 (31.9)
 Multivessel coronary artery disease NA NA NA 4213 (59.6)
 History of PCI† 3025 (41.8) 1840 (34.9) 391 (23.3) 5837/7066 (82.6)
 More than one myocardial infarction 830 (11.5) 804 (15.2) 191 (11.4) 1188 (16.8)
 Peripheral arterial disease 449 (6.2) 400 (7.6) 101 (6.0) 404 (5.7)
 eGFR <60 mL/min/1.73m2* 2402 (37.5) 2383 (49.9) 797 (52.3) 1649 (23.6)
Drug treatment:
 Any aspirin 5726 (79.1) 4118 (78.0) 1250 (74.6) 7057 (99.9)
 Clopidogrel 3713 (51.3) 2628 (49.8) 0 (0) NA
 Statins 6262 (86.5) 4500 (85.2) 1335 (79.7) 6583 (93.2)
 β blockers 5098 (70.4) 3574 (67.7) 1065 (63.5) 5878 (83.2)
 ARBs/ACEIs 5793 (80.0) 4145 (78.5) 1283 (76.6) 5697 (80.6)
STEMI=ST elevation myocardial infarction; IQR=interquartile range; NA=not available; PCI=percutaneous coronary intervention; eGFR=estimated 
glomerular filtration rate; ARBs=angiotensin II receptor blockers; ACEIs=angiotensin converting enzyme inhibitors.
*Information from CALIBER available for 65% for weight, 94% for smoking status, and 88% for eGFR.
†In past 365 days.
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follow-up (fig 2, table C in appendix 1). This was most 
marked for ADP receptor inhibitors, which declined to 
<10% at three years.
Cardiovascular events
In CALIBER’s target, high risk, and real world popula-
tions the three year Kaplan-Meier rates for a composite 
outcome of acute myocardial infarction, stroke, or fatal 
cardiovascular disease were 18.8% (95% confidence 
interval 16.3% to 21.8%), 21.7% (20.1% to 23.3%), and 
17.2% (16.0% to 18.5%), respectively, compared with 
9.04% in the trial placebo group (table 2 , fig 3 ). Patterns 
of all cause mortality were similar (fig A in appendix 2). 
With adjustment for age and sex the three year Kaplan-
Meier composite outcome rate for the target population 
declined (13.9%, 10.8% to 17.9%), and the difference 
between the high risk and real world populations 
largely disappeared (17.9% (15.9% to 0.2%) and 17.2% 
(15.5% to 19.1%)). In CALIBER subgroups defined by age 
≥65, one or more previous acute myocardial infarctions, 
Fig 2 | Proportion of patients prescribed drugs for secondary prevention from date of index Mi (one year before study entry) and up to three years of 
follow-up adjusted for censoring (assuming continuous coverage between first and last prescriptions issued). aCei=angiotensin converting enzyme 
inhibitors; aDP=adenosine diphosphate; arbs=angiotensin ii receptor blockers
table 2 | Observed cumulative event rate (%) of clinical outcomes and number of events prevented or harms caused, applying trial results to uK patients 
who survived myocardial infarction (Mi) defined in study (with 95% Ci)
Population based observational data
Pegasus-tiMi-54 
trial placebo arm 
(n=7067)
all post-Mi 
survivors “real 
world” (n=7238)
Met trial inclusion 
criteria “high 
risk” (n=5279)
Met trial inclusion 
and exclusion criteria 
“target” (n=1676)
Mi/stroke/fatal cardiovascular disease
3 year cumulative risk (%) 17.2 (16.0 to 18.5) 21.7 (20.1 to 23.3) 18.8 (16.3 to 21.8) 9.04
No of events prevented/year/per 10 000 patients treated applying risk reduction 
in PEGASUS-TIMI-54 trial*
92 (86 to 99) 116 (108 to 125) 101 (87 to 117) —
Fatal, severe, or intracranial bleeding
3 year cumulative risk (%) 2.3 (1.8 to 2.9) 3.0 (2.4 to 3.8) 3.0 (2.0 to 4.4) 1.26
No of excess harms/year/10 000 patients treated applying risk increase in 
PEGASUS-TIMI-54 trial*
58 (45 to 73) 75 (60 to 95) 75 (50 to 110) —
*PEGASUS-TIMI-54 trial estimates (ticagrelor 60 mg v placebo; intention to treat estimates) for cardiovascular death, stroke, or myocardial infarction (hazard ratio 0.84, main report4 ), TIMI 
major bleeding (relative risk 1.75, supplementary appendix in main report4) were used to calculate cardiovascular events prevented and harms caused per 10 000 treated per year.
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diabetes, and renal disease, the age-sex adjusted risk of 
recurrent myocardial infarction, stroke, or death was 
24.8%, 32.3%, 20.8%, and 22.8%, respectively (fig 4). 
Applying three year relative risk reduction for trial par-
ticipants treated with ticagrelor 60 mg daily, we calcu-
lated that 101 (95% confidence interval 87 to 117) 
ischaemic events were prevented per 10 000 treated per 
year for the target group. The same relative risk reduc-
tion applied to the high risk and real world populations 
suggested at least 116 (108 to 125) and 92 (86 to 99) 
events were prevented.
bleeding events
In CALIBER’s target, high risk, and real world popula-
tions the three year Kaplan-Meier rates for fatal, severe, 
or intracranial bleeding were 3.0% (95% confidence 
interval 2.0% to 4.4%), 3.0% (2.4% to 3.8%), and 2.3% 
(1.8% to 2.9%), respectively, compared with 1.26% for 
TIMI major bleeding in the trial placebo group (table 2 , 
fig 3). The three year rates of fatal or intracranial bleed-
ing in the three CALIBER populations were about twice 
the 0.6% rate in the trial. Applying three year relative 
risk increase for trial participants treated with ticagre-
lor 60 mg daily, we calculated that an extra 75 (95% con-
fidence interval 50 to 110), 75 (60 to 95), and 58 (45 to 73) 
fatal, severe, or intracranial bleeds per 10 000 treated 
per year occurred in the target, high risk, and real world 
populations, respectively. For fatal or intracranial 
bleeding, excess events per 10 000 treated per year were 
10 (6 to 18), 10 (7 to 14), and 8 (6 to 10), respectively 
(table D in appendix 1).
sensitivity analysis
We found high event rates among patients censored in 
the first year, which did not differ according to clopido-
grel prescription status at study entry. Event rates also 
did not differ according to status two years after the 
index acute myocardial infarction (approximating to 
the median 1.7 years that characterised PEGA-
SUS-TIMI-54 trial entry), suggesting that the observed 
difference in event rates between CALIBER and PEGA-
SUS-TIMI-54 is unlikely to be biased by continuing 
clopidogrel use (table E in appendix 1).
discussion
Principal findings
Both trial evidence and real world evidence are required 
to inform decisions about adding prolonged dual anti-
platelet therapy to the combination of drugs recom-
mended for secondary prevention of myocardial 
infarction. In this novel comparison of participants in a 
major randomised trial (PEGASUS-TIMI-54) with unse-
lected population based data from linked primary and 
secondary care electronic health records (CALIBER)4 11 
Fig 3 | Kaplan-Meier risks of ischaemic and bleeding events in Caliber’s real world, high risk, and target populations of patients surviving one year or 
more after acute myocardial infarction
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we found that only about a quarter of all patients a year 
after acute myocardial infarction met trial inclusion and 
exclusion criteria. The cardiovascular risk in this “tar-
get” population was high compared with the trial popu-
lation, with about twice the rate of non-fatal and fatal 
cardiovascular events in the subsequent three years. 
Our analysis indicates that addition of ticagrelor to the 
treatment regimen of these patients might prevent 101 of 
these events each year for every 10 000 patients treated, 
at the cost of 75 major bleeds. This ratio is almost identi-
cal to the calculation reported in the main trial results 
(42 v 31), although the absolute magnitude of potential 
net benefit of 26 is greater in the real world data.
Comparison with previous studies
In comparing the population characteristics and out-
comes of PEGASUS-TIMI-54 with real world populations 
drawn from electronic health records we have contextu-
alised the trial’s findings and potential relevance to 
patient care. Previous studies have reported the limited 
generalisability of clinical trial populations, but 
 comparisons have usually been with small hospital 
based samples without development of target popula-
tions defined by inclusion and exclusion criteria to 
allow more precise assessment of patient representa-
tiveness.22-24 These studies have been further limited by 
their focus on patients’ characteristics without consid-
eration of outcomes to allow estimation of how treat-
ment effects might translate into benefits for real world 
patients. We dealt with these limitations by providing 
an electronic health record resource to develop a target 
population drawn from primary care with follow-up for 
benefit and harm outcomes.
Mismatch between target and trial populations
The novel use of primary-secondary care linked elec-
tronic health records has shown a large “healthy trial 
participant” effect, and, despite only about a quarter of 
our real world patients meeting PEGASUS-TIMI-54 
inclusion and exclusion criteria, reflecting the limited 
generalisability of trial populations, their cardiovascu-
lar outcomes were considerably worse. The mismatch 
between the target and trial populations was reflected 
in differences in demographic and clinical characteristics, 
Fig 4 | Kaplan-Meier risks of myocardial infarction/stroke/fatal cardiovascular disease for patient subgroups defined by age, diabetes, one or more previous 
acute Mi, and renal disease (indicated by egFr) in Caliber “real world” population. age adjusted except for age subgroup analyses. Multivariate adjustment 
included age (not for age subgroup analyses), sex, diabetes, more than one Mi, and renal disease. reported CvD risk at third year of follow-up for reference 
patient characteristics: age 71 (median age of study population), male, no diabetes, no more than one previous Mi, and no chronic renal disease
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the target population being considerably older and with 
a higher proportion of women. The preponderance of 
non-STEMI in the target population is consistent with 
many recent reports25-27 and, together with the earlier 
recruitment start date compared with the trial popula-
tion (2005 v 2010), accounts for the relatively low rate of 
percutaneous coronary intervention that we and others 
have previously reported for UK hospitals.28 Many real 
world patients who were receiving dual antiplatelet 
therapy for a year or more year after acute myocardial 
infarction were excluded in development of the target 
population, and this might have resulted in minor exag-
geration of healthy trial participation as the trial 
patients were enrolled during a wider, one to three year 
recruitment window. Nevertheless, our comparison of 
patients’ characteristics in the CALIBER and PEGA-
SUS-TIMI-54 populations was revealing in helping to 
understand the differences in cardiovascular outcome 
and the potential generalisability of the trial results. 
The methods we report are scalable, and our study sug-
gests that such linked electronic health record resources 
could provide useful “real world evidence” for trials in 
other clinical settings.
Cardiovascular risk late after myocardial infarction
A major finding in our study was the high cardiovascu-
lar risk of the whole population of patients who sur-
vived a year or more after acute myocardial infarction, 
consistent with a report from Sweden29  published 
before the PEGASUS trial results were available. Thus, 
the patients in CALIBER’s target population had a three 
year event rate twice that of participants in the trial, no 
doubt reflecting differences in simple risk factors,30-32 
with adjustment for age and sex resulting in substantial 
reductions in event rates. The high event rate in CALI-
BER’s target population showed only minor attenuation 
in the real world population, indicating comparable 
potential for risk reduction with dual antiplatelet ther-
apy given to all patients surviving a year or more after 
acute myocardial infarction. Accordingly, our estima-
tion of ischaemic events prevented by ticagrelor 60 mg 
was similar for both target and real world populations 
and yet was greater for the high risk population defined 
by trial inclusion criteria. The Committee for Medicinal 
Products for Human Use of the European Medicines 
Agency has recently claimed that in patients with previ-
ous acute myocardial infarction who are at high risk of 
atherothrombotic events, treatment with ticagrelor 60 
mg can be started as continuation treatment after an 
initial one year of treatment with dual antiplatelet ther-
apy.33  Our findings support this view and indicate that 
the potential for dual antiplatelet therapy for a year or 
more after acute myocardial infarction to deliver clini-
cal benefit is likely to be greatest in high risk subgroups, 
such as those defined in figure 4, that fulfil PEGA-
SUS-TIMI-54 inclusion and exclusion criteria
benefits and harms of prolonged dual antiplatelet 
therapy
Only about half of CALIBER’s populations were pre-
scribed clopidogrel at baseline (a year or more year after 
acute myocardial infarction), and prescription rates fell 
sharply thereafter in accordance with current guideline 
recommendations. Nevertheless, a small proportion of 
patients in CALIBER’s high risk and real world popula-
tions remained taking clopidogrel well after the first 
year (table C in appendix 1), but the analysis in table E 
in appendix 1 shows that outcomes were similar regard-
less of ongoing treatment, indicating that observed dif-
ferences in event rates between CALIBER and 
PEGASUS-TIMI-54 were unlikely to be biased by contin-
ual clopidogrel use. The results of PEGASUS-TIMI-54 
suggest that stopping P2Y12 receptor antagonists after 
the first year might be a missed treatment opportunity 
for reducing ischaemic events. The potential benefit of 
adding, or continuing, a P2Y12 receptor antagonist, 
however, must be weighed against the increased risk of 
bleeding reported in the trial. Fatal, severe, or intracra-
nial bleeding, an approximation of the TIMI major 
bleeding endpoint in PEGASUS-TIMI-54, occurred more 
commonly in CALIBER’s target population than in the 
trial population, but our estimation of bleeding events 
caused by ticagrelor in the real world population was 
25% lower than cardiovascular events prevented. In 
selecting patients for dual antiplatelet therapy for a 
year or more after acute myocardial infarction, the bal-
ance between cardiovascular benefit and risk of bleed-
ing needs careful consideration, with recognition that 
patients and clinicians might have different views 
about their relative importance. The cumulative three 
year incidence of the most feared bleeding endpoints— 
fatal or intracranial haemorrhage—was only 1.4% in the 
high risk population for whom the benefits of treatment 
in terms of cardiovascular events prevented was great-
est. Nevertheless, this residual risk of bleeding empha-
sises the importance of PEGASUS-TIMI-54 exclusion 
criteria, particularly previous stroke or recent anticoag-
ulation therapy, in selecting patients for dual antiplate-
let therapy.
Our analyses of benefit and harm suggested a net 
benefit of treatment with dual antiplatelet therapy for a 
year or more after acute myocardial infarction, reflected 
in the 99 target population patients needed to treat to 
prevent one ischaemic event compared with the 133 
needed to cause one TIMI major bleed and 1000 to 
cause one fatal or intracranial bleeding event. Dual 
antiplatelet therapy for a year or more after acute myo-
cardial infarction might, therefore, be considered in 
selected patients without previous stroke or anticoagu-
lant therapy who are at greatest risk of recurrent isch-
aemic events. Our data showed that those aged ≥65, 
with diabetes, chronic renal disease, or previous acute 
myocardial infarction had a particularly high age-sex 
adjusted risk of recurrent acute myocardial infarction, 
stroke, or death, ranging from 20.8% to 32.3%. Our data 
also showed that across all CALIBER populations, how-
ever, adherence to secondary prevention drugs declined 
steeply during follow-up, despite high prescription 
rates after discharge after the index event. Non-adher-
ence to secondary prevention drugs after acute myocar-
dial infarction has been widely reported34-36 and for 
most patients must represent a more important target 
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for improving outcomes than extended dual antiplate-
let therapy.
implications of findings
Our findings have implications for guideline groups 
and clinicians. Guideline groups should seek to deter-
mine the representativeness of participants in clinical 
trials and the potential public health impact in terms of 
numbers of events prevented or harms caused in target 
and real world populations. The electronic health 
record resource we describe is scalable and offers con-
siderable potential for answering these questions, 
thereby placing trial results in a clinical context. The 
clinical implications of our study are also relevant in 
addressing the applicability of trial findings in the con-
sulting room. This is a question that commonly con-
fronts clinicians, and the methods we present provide a 
novel means of addressing it. Our study also identifies a 
need for careful clinical supervision of patients who 
survive a year or more after acute myocardial infarction. 
It was an important observation that use of secondary 
prevention drugs declined progressively while isch-
aemic event rates were in steep ascent. This applied to 
all drug classes and represents a missed opportunity to 
protect these high risk patients against ischaemic 
events.
strengths and weaknesses
A particular strength of this study lies in its use of CAL-
IBER’s linked electronic health records to assemble 
large target and real world populations for comparison 
with participants in a major randomised trial. In sourc-
ing our real world patients from linked electronic health 
records, without exclusions and regardless of what 
treatment they received, we avoided confounding by 
indication and minimised biases in recruitment and fol-
low-up. Data quality has been verified in studies that 
have established the diagnostic and prognostic validity 
of a range of risk factors.16-20  We have further assured 
highly complete event ascertainment, the diagnostic 
validity of primary care and hospital admission records 
for acute myocardial infarction showing positive pre-
dictive values of 92.2% and 91.5%, respectively, com-
pared with a “ideal standard” diagnosis based on 
troponin values, findings on electrocardiography, and 
cardiological assessment in the MINAP disease regis-
try.12  Moreover, there was no loss to follow-up in our 
CALIBER population in contrast with PEGASUS-TIMI-54. 
Other investigators have reported on event ascertain-
ment within linked dual antiplatelet therapy. A compar-
ative analysis within the West of Scotland Coronary 
Prevention Study (WOSCOPS) population concluded 
that it can be “as effective as reporting based on direct 
contact with patients.”37  Twenty year follow-up for car-
diovascular events recorded in electronic health records 
has now been reported.38
It was a limitation of our study that we were unable to 
compare severity of coronary disease between the two 
populations as this information is unavailable in CALI-
BER. This is unlikely to have affected our conclusions, 
however, as there was no apparent heterogeneity in the 
efficacy of ticagrelor with respect to the severity of coro-
nary disease in the trial. It was a further limitation of 
our study that we were able to provide a precise match 
for only two of the TIMI major bleeding criteria,39 the 
third criterion (≥50 g/L fall in haemoglobin concentra-
tion) required proxies: admission to hospital for bleed-
ing with length of stay of seven days or more or need for 
blood transfusion. PEGASUS-TIMI-54’s other harm end-
point—fatal or intracranial bleeding—was matched in 
our CALIBER population. Estimates of the harms and 
benefits of extended dual antiplatelet therapy are based 
on relative risks calculated in PEGASUS-TIMI-54. The 
estimates are likely robust for the target group matched 
for trial selection criteria but require more cautious 
interpretation in the high risk and real world popula-
tions.
Conclusions
In summary, this novel comparative analysis has shown 
that patients who survive a year or more after acute 
myocardial infarction remain at substantial risk of fur-
ther cardiovascular events. The PEGASUS-TIMI-54 trial 
was one of the first to inform management of this under-
studied group. It recruited high risk patients, but our 
study has shown that real world patients who survive a 
year or more are at yet greater risk, amplifying the 
potential of dual antiplatelet therapy to improve prog-
nosis. This potential must be weighed against the risk of 
bleeding and is likely to be greatest in high risk sub-
groups without previous stroke or recent anticoagula-
tion therapy.
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